2019-04-09 23:15
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting on Thursday 2 May 2019 at 13.00 pm CET at Baker & McKenzie's premises at Vasagatan 7 in Stockholm. The doors to the meeting...
2019-04-09 22:30
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION...
2019-04-09 17:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION...
2019-04-01 08:00
Uppsala, Sweden, April 1, 2019. Biovica receives an additional patent on the US market for the company PCR-based product.
2019-03-21 08:00
Significant events during the third quarter
· Abstract was presented at San Antonio Breast Cancer Symposium
· New office and staff in USA
Significant events after the end of the period
· Abstract to be presented at AACR in April
· Shares...
2019-03-20 17:00
Uppsala, Sweden, March 20, 2019. Lars Holmqvist was elected Chairman of the Board and a warrant program of 175,000 options to the Board was approved.
2019-03-19 08:00
Uppsala, the 19th of March 2019. Two new customers have purchased DiviTum®-kits in order to evaluate response to treatment in breast cancer studies. The customers are pharma- and CRO-companies (Contract Research Organization) based in US and Europe...
2019-03-18 08:00
On March 21, 2018, at 08:00 am CET, Biovica International AB (publ) will publish its interim report for the third quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on...
2019-03-04 07:56
Uppsala, March 4, 2019. Biotechnology company Biovica announces today that Nasdaq has approved the company’s application to move from Nasdaq First North to be listed on Nasdaq First North Premier. The transition is an important part of the ambition...
2019-02-28 07:57
New DiviTum results from a clinical study led by Dr Luca Malorni from the Prato Hospital, Italy will be presented at the American Association of Cancer Research annual meeting, 29 March-3 April, in Atlanta. The study results show that DiviTum can evaluate...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects